Barclays Upgrades Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) to “Strong-Buy”

Barclays upgraded shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of OTCMKTS BIOVF opened at $28.30 on Wednesday. The company has a current ratio of 0.73, a quick ratio of 0.49 and a debt-to-equity ratio of 0.30. The stock has a market cap of $10.07 billion, a P/E ratio of 47.97 and a beta of 0.51. The stock has a 50 day moving average of $28.88 and a two-hundred day moving average of $28.35. Swedish Orphan Biovitrum AB has a twelve month low of $22.87 and a twelve month high of $32.25.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.